Q&A

ACE inhibitors are better than diuretics for treatment of hypertension in the elderly

Author and Disclosure Information

  • BACKGROUND: The recent ALLHAT study compared the diuretic chlorthalidone with the ACE inhibitor lisinopril and the calcium-channel blocker amlodipine for treating hypertension in patients aged 55 years and older who had at least 1 other coronary heart disease risk factor.1
  • POPULATION STUDIED: A total of 6083 subjects with hypertension, aged 65 to 84 years and mostly of European ancestry, were enrolled from 1594 family medical practices throughout Australia. Hypertension was defined as an average of 2 systolic blood pressure readings of at least 160 mm Hg, or an average diastolic blood pressure of at least 90 mm Hg with a systolic blood pressure of at least 140 mm Hg.
  • STUDY DESIGN AND VALIDITY: In this randomized, nonblinded study, subjects were followed for a median of 4.1 years, with a blinded assessment of endpoints. Allocation was concealed. Previous antihypertensive drug therapy was discontinued at least 1 week prior to entry.
  • OUTCOMES MEASURED: The primary endpoint was the combined rate of all cardiovascular events or death from any cause. Investigators also measured blood pressure and cause-specific cardiovascular events (fatal and nonfatal).
  • RESULTS: By the study’s end, approximately 60% of the subjects were still receiving their assigned treatment. Sixty-five percent of the ACE inhibitor group and 67% of the diuretic group were receiving monotherapy. The reduction of blood pressure was similar in both groups.


 

PRACTICE RECOMMENDATIONS

Despite similar reductions in blood pressure, angiotensin-converting enzyme (ACE) inhibitors demonstrate lower combined rates of cardiovascular events or all-cause mortality in elderly hypertensive patients compared with diuretics. This benefit is most evident in men.

These results may differ from those of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) trial because that study included younger patients, had a greater representation of patients with African ancestry, used different brands of medication, and had a slightly different primary outcome. Despite these differences, both treatments offer an inexpensive means for reducing blood pressure and preventing hypertension-related complications.

Recommended Reading

Tools for rapid preoperative cardiovascular risk assessment
MDedge Family Medicine
What is the most effective beta-blocker for heart failure?
MDedge Family Medicine
Early invasive strategy for acute cardiac ischemia is cost effective
MDedge Family Medicine
Detriments of tPA for acute stroke in routine clinical practice
MDedge Family Medicine
Digoxin increases mortality among women with congestive heart failure
MDedge Family Medicine
HRT and vitamins C and E do not improve coronary disease in women
MDedge Family Medicine
What are the risks of long-term NSAIDs and COX-2 inhibitors?
MDedge Family Medicine
Is rate control better than rhythm control for atrial fibrillation in older high-risk patients?
MDedge Family Medicine
Does magnesium therapy early in acute MI reduce mortality?
MDedge Family Medicine
Does C-reactive protein predict cardiovascular events in women better than LDL?
MDedge Family Medicine